Positron Corporation Secures Multiple PET-CT Orders from Leading Nuclear Cardiologist Practices
MWN-AI** Summary
Positron Corporation, a leader in molecular imaging technology, has marked a significant milestone by securing orders for four PET-CT 64-slice scanners from three prominent nuclear cardiology practices led by esteemed physicians. This announcement, made on February 17, 2026, highlights Positron's expanding footprint in advanced cardiovascular diagnostics, underscoring the increasing adoption of its state-of-the-art PET-CT technology.
These new customer engagements reflect a broader trend within the nuclear cardiology sector, where providers are transitioning from older imaging modalities to advanced solutions that promise both enhanced clinical outcomes and operational efficiency. Adel Abdullah, President and Chairman of Positron, emphasized that the increasing preference for cardiac PET technology demonstrates growing confidence in its clinical performance and economic sustainability.
Positron's PET-CT scanners are designed to provide high-resolution imaging for both cardiac and oncology applications while minimizing patient radiation exposure through high-sensitivity detector technology. The innovative design, featuring a 72cm wide-bore gantry and compact footprint, ensures patient comfort and adaptability to a variety of clinical environments.
With over thirty years in the industry, Positron is positioned as a reliable partner for nuclear cardiology practices, offering not just cutting-edge imaging technology, but also comprehensive clinical, technical, and training support. This multidimensional approach allows healthcare providers to transition smoothly to PET-CT imaging while enhancing diagnostic capabilities.
Moreover, Positron’s commitment to advancing the field of cardiac and oncology imaging, bolstered by its collaboration with Shenyang Intelligent Neuclear Technology Co., underscores its dedication to delivering top-tier technology and value to healthcare providers. This strategic positioning aims to enhance the diagnosis of coronary artery disease and improve patient outcomes in an increasingly competitive medical landscape.
MWN-AI** Analysis
Positron Corporation (OTC: POSC) has recently secured multiple orders for its advanced PET-CT scanners from leading nuclear cardiology practices, marking a significant milestone in its strategic growth within the molecular imaging market. The sale of four 64-slice PET-CT scanners, along with long-term service agreements, highlights the increasing demand for next-generation imaging technologies in cardiovascular diagnostics.
Investors should recognize several key factors that position Positron favorably in the marketplace. First, the company's specialized focus on cardiac and oncology imaging aligns with the ongoing transition from traditional imaging modalities to more advanced solutions like PET-CT that offer superior clinical outcomes and efficiency. As cardiac PET imaging continues to gain traction, driven by its ability to provide high-resolution and functional information, Positron stands to benefit from a growing customer base seeking cutting-edge diagnostic equipment.
Furthermore, the comprehensive support systems that Positron implements—including technical and training services—enhance its competitive edge, fostering strong customer relationships and long-term partnerships. The distinct advantages of its technology, including a compact design and advanced imaging capabilities, further solidify Positron's appeal in diverse clinical settings.
In terms of market outlook, with an aging population and heightened focus on early and accurate disease diagnosis, the demand for PET-CT technology is expected to grow, positioning Positron for substantial revenue potential. Investors should monitor upcoming financial results in 2026, aiming to gauge the company’s ability to translate increased sales into sustainable profitability.
However, it is important to note that investing in Positron carries inherent risks, including market volatility and reliance on the successful deployment of its technology. Hence, prudent investors should weigh these factors, stay informed on industry trends, and consider incorporating Positron shares as part of a diversified portfolio focusing on healthcare technology advancements.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Buffalo, NY, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64-slice scanners, along with associated long-term services agreements, to three distinguished nuclear cardiology practices led by nationally recognized physicians specializing in advanced cardiovascular diagnostics and interventional care.
These new customer engagements underscore the adoption of Positron’s next-generation PET-CT technology and comprehensive services solution. Nuclear cardiology practices are increasingly selecting Positron not only for its advanced imaging capabilities, but also for its fully integrated clinical, technical, and training support that is designed to ensure operational reality, efficiency and long-term value.
“As cardiac PET continues to replace legacy imaging modalities, providers are increasingly seeking solutions that deliver both superior clinical performance and sustainable, viable economics,” said Adel Abdullah, President and Chairman of Positron Corporation. “This continued adoption reflects growing confidence in the modality and recognition of Positron’s ability to support practices with advanced PET-CT technology, exceptional service, and a true partnership-oriented approach.”
Engineered to optimize both clinical outcomes and operational efficiency, Positron’s PET-CT scanners provide high-resolution anatomic and functional imaging for both cardiac and oncology applications. Key features include a 72cm wide-bore gantry for enhanced patient comfort, high-sensitivity detector technology that supports reduced radiation exposure, and a compact footprint, the smallest and lightest in its class, making it ideal for most all clinical environments.
Positron’s advanced data acquisition capabilities deliver fast, high precision imaging, enhancing diagnostic confidence while expanding the scope of studies physicians can perform, from myocardial perfusion to tumor detection and neurological assessments.
With more than three decades of experience supporting tens of thousands of clinical scans nationwide, Positron continues to position itself as a trusted partner to nuclear cardiology practices seeking to transition to PET-CT imaging with confidence, efficiency, and long-term economic value.
About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's PET and PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Please visit the Company’s website at: www.positron.com.
Forward-Looking Statements
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: [email protected]
FAQ**
How is Positron Corp. (POSC) leveraging its advanced PET-CT technology to enhance the operational efficiency of nuclear cardiology practices?
What strategic advantages does Positron Corp. (POSC) hold over competitors in the cardiac and oncology imaging segments?
Can you elaborate on the long-term services agreements associated with the sale of PET-CT scanners by Positron Corp. (POSC) to differentiate itself from other providers?
What role does Positron Corp. (POSC) see its partnership with Shenyang Intelligent Neuclear Technology Co. playing in the future of molecular imaging technology?
**MWN-AI FAQ is based on asking OpenAI questions about Positron Corp. (OTC: POSC).
NASDAQ: POSC
POSC Trading
5.99% G/L:
$2.512 Last:
31,308 Volume:
$2.46 Open:
